Boxing Zhentong Powder Veterinary Grade API is supplied under the commercial model name Boxing Zhentong Powder Veterinary Grade API as a crystalline active pharmaceutical ingredient intended for further processing into tablets, injections, capsules, powders, granules, premix batches, and liquid solutions. The manufacturer’s model differentiation separates the injectable-grade material from the feed-premix grade by bacterial endotoxin load, powder flow character, bulk density, and residual solvent profile. Packaging is normally 25 kg HDPE drums with double LDPE liners; desiccant units are added when the ambient relative humidity during storage exceeds 60%. The material is not a finished veterinary medicinal product and is not supplied as sterile. Each route of administration imposes a separate set of processing limits, and the certificate of analysis for the specific lot takes precedence over general technical descriptions.

The API is released as a multi-route active substance rather than as a single monolithic grade. Injectable-grade lots are tested for bacterial endotoxins using Ph. Eur. 2.6.14 or USP <85>; feed-premix lots are tested for sieve retention, dusting potential, and bulk density. This route-dependent specification is the principal structural difference from single-grade API powders used only for oral or topical applications. Published pharmacopoeial monographs for this specific product are limited, and the supplier’s current technical data sheet should be consulted for lot-specific acceptance criteria.

What release specifications and pharmacopoeial methods define the injectable and feed-premix grades?

Release testing is organized around identity, purity, residual solvent, particle size, and microbial quality parameters. The following matrix lists the analytical framework described in the supplier’s technical data sheet. Acceptance criteria for a given lot are lot-specific, but the supplier’s published framework uses the following route-dependent limits.

Residual solvents are controlled under VICH GL18. The supplier’s dried material is manufactured to reduce Class 1 solvents below the limits set out in the guideline and to report selected Class 2 solvents on the certificate of analysis. Identity is confirmed by infrared absorption and HPLC retention time against a qualified reference standard. Injectable-grade lots are additionally tested for sub-visible particulate matter after reconstitution in Water for Injection using Ph. Eur. 2.9.19 or USP <788>. The solid-state form is monitored by X-ray powder diffraction using Ph. Eur. 2.9.33; unassigned reflections above the limit of detection are considered non-conforming.

Direct compression of the tablet grade requires control of blend time, shear input, and lubricant selection. In production-scale high-shear mixers with a working capacity of 600 L to 1200 L, the API is first passed through a 0.8 mm screen and blended with microcrystalline cellulose and croscarmellose sodium for 10 min at impeller speeds below 25 rpm to avoid shear-induced particle fracture. Magnesium stearate is added only during the final 3 min of blending. The manufacturer’s particle size control to D90 ≤75 µm is intended to maintain content uniformity at low dose strengths; published data for this specific configuration is limited. Rotary tablet press settings are formulation-dependent, but immediate-release formulations are typically compressed to a target hardness of 50 N to 80 N, with a pre-compression force of 2 kN to 4 kN and a main compression force of 10 kN to 18 kN. Loss on drying at ≤1.0% reduces sticking during prolonged compression runs under ambient conditions below 60% RH. At residual moisture above 1.0%, powder bridging may occur in the feed frame.

Wet granulation is acceptable when dry blending cannot provide sufficient flow. In a high-shear granulator with a bowl capacity of 150 L, the endpoint is monitored by torque or impeller power consumption rather than by fixed time alone. The binder solution is added slowly because the API’s solubility profile is pH-dependent. Overwetting produces dense agglomerates that are difficult to mill and can shift the dissolution profile. Granules prepared from this API should be dried to a moisture content below 1.0% before final blending. If fluid-bed granulation is used, the inlet air temperature should be kept within the supplier’s stated range to avoid polymorphic conversion; published data for this specific configuration is limited.

If sterile filtration of a reconstituted solution is planned

Solution formulations of Boxing Zhentong Powder Veterinary Grade API require a pre-filtration bioburden reduction step because the API is not supplied as sterile. The injectable-grade powder is reconstituted in Water for Injection at a temperature controlled between 20 °C and 25 °C, with gentle agitation in a stainless-steel vessel. The solution is then passed through a 0.45 µm clarifying filter followed by a 0.22 µm sterilizing-grade membrane filter. Filter compatibility must be confirmed because certain nylon membranes may adsorb the active moiety; polyethersulfone or polyvinylidene difluoride filters are used in the supplier’s filter validation studies. The terminal solution should be processed under a nitrogen overlay if the formulation is oxygen-sensitive. The API should not be combined with strong oxidizing agents or amine-based buffers that can raise pH above the stability range specified in the supplier’s development report.

Endotoxin control before filtration is critical: the incoming API limit of <0.5 EU/mg does not replace terminal sterilization or aseptic processing controls. If terminal sterilization is used, the thermal cycle must be matched to the solution pH, container headspace, and antioxidant content. For heat-sensitive formulations, aseptic filtration followed by filling in a grade A environment remains necessary. Filter validation and media fill simulation are required for each filling line. The solution should be protected from light if the API is photolabile. Published data for this specific configuration is limited, and site-specific validation is expected.

For capsules, the same D90 ≤75 µm specification allows direct filling into hard gelatin capsules without slugging or wet granulation. Powder flow is evaluated by the Hausner ratio; the supplier’s granular grade typically gives a Hausner ratio between 1.15 and 1.35, which is acceptable for semi-automatic capsule filling equipment. Powders and granules for oral administration can be prepared by dry granulation or fluid-bed granulation. The premix grade is not intended for direct parenteral use. If the capsule fill is intended for administration to neonatal animals, the formulation should be assessed for gastric pH effects because the dissolution rate may be slower than in adult animals.

Premix Segregation, Carryover, and Mixer Validation Constraints

Feed premix batches require separate mixer validation because the API tends to segregate when its particle size differs substantially from the carrier. The manufacturer’s premix grade is densified to a bulk density close to that of limestone or corn-cob carrier, which reduces fines elutriation during transfer. In a double-ribbon mixer with a working volume of 500 kg to 2000 kg, the API is added by geometric dilution rather than dumped at the top. Mixing times are established by assay uniformity sampling at 10 min, 15 min, and 20 min; the acceptance criterion for blend uniformity is typically a relative standard deviation of ≤5.0% across 10 sampling points. Carryover of the active substance into subsequent batches is determined by cleaning validation using rinse or swab samples analyzed by HPLC.

The premix grade should not be conveyed over long distances using pneumatic transfer without assessing particle attrition. Sieve analysis using ISO 3310-1:2016 is applied to detect oversized agglomerates and excessive fines. Dusting potential is controlled because airborne fines create cross-contamination risk and operator exposure. Local exhaust ventilation and dust-tight transfer systems are required when handling the dry powder at production scale. The mixer-specific data should be generated under actual production conditions because published data for this specific configuration is limited.

Liquid oral solutions can be prepared from the granular grade. The powder is added to the aqueous phase under high-shear mixing until fully dissolved, then pH is adjusted with dilute hydrochloric acid or sodium hydroxide solution according to the manufacturer’s stability window. Storage of bulk solution should be limited to 24 h at 2 °C to 8 °C unless the formulation contains a validated antimicrobial preservative. The solution should be protected from light if photostability data indicate degradation. Filtration through a 5 µm or 1 µm cartridge is often sufficient for oral liquids; injectable solutions require the stricter filtration train described above.

What Distinguishes This Grade from General-Purpose API Powders in Multi-Route Manufacturing?

Compared with a generic API powder sold only for oral administration, the veterinary grade applies an injectable-grade endotoxin specification, and the particle size distribution is controlled for both dry blending and liquid dissolution. The feed-premix grade is densified to reduce segregation and airborne dust, which is a distinction from micronized API powders that are difficult to blend into feed matrices. Another difference is the residual solvent control strategy: the supplier applies VICH GL18 limits for Class 1 solvents and selected Class 2 solvents, and the certificate of analysis lists the actual residue values for each lot.

The multi-route designation does not remove the need for formulation-specific stability studies. The product is not a sterile API; aseptic processing or terminal sterilization of the finished dosage form remains mandatory for injectable products. The grade is also differentiated by its documentation package, which includes route-specific release data, residual solvent values, and particle size results for each lot. These controls reduce the burden on downstream manufacturers but do not replace process validation, filter validation, or cleaning validation at the finished-product facility.

The product should be stored in a dry area below 25 °C. If the ambient relative humidity exceeds 60%, pre-drying at 40 °C to 50 °C for 2 h to 4 h may be required before dry blending. Containers should be resealed immediately after use because the powder is hygroscopic. The shelf life stated on the certificate of analysis applies only to unopened containers; after first opening, the material should be used within the period defined by the site’s quality risk assessment. Avoid combination with strong oxidizing agents, amine-based buffers, and high-pH aqueous media unless stability data support the specific formulation.